A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome The Philadelphia (Ph) chromosome is present in more than 95% cases of chronic myeloid leukemia (CML) and encodes the Bcr-Abl oncoprotein with constitutive tyrosine kinase activity, which is believed to be crucial in cell transformation. Only rare cases of CML are truly negative for both the Ph chromosome and BCR-ABL1 rearrangement. 1 The presence of a late-appearing Ph chromosome in patients with acute myelogenous leukemia (AML) represents a very infrequent occurrence. 2 Therapy with imatinib mesylate (Gleevec) renders sustained hematologic responses in 95% of patients in early chronic phase CML and 31-69% in advanced phase CML.
3 AMN107 is a phenylamino-pyrimidine derivative 20 to 30-fold more potent as an Abl inhibitor than imatinib, which renders hematologic response rates ranging from 44 to 89% and cytogenetic responses ranging from 22% in blast phase to 29% in accelerated phase and 50% in chronic phase (Kantarjian et al. Blood 2005; 106: 15a, abstract).
We report a patient with AML who developed a novel t(3;21)(p21;q22) during the course of therapy. Shortly thereafter, he exhibited a late-appearing Ph chromosome. Therapy with the tyrosine kinase inhibitors imatinib mesylate and AMN107 was completely unsuccessful.
A 62-year-old man with history of leukopoenia since 1990 underwent a bone marrow aspiration and biopsy in February 2002 owing to worsening pancytopenia. A diagnosis of myelodysplastic syndrome (MDS) with a normal diploid male karyotype was made and the patient was initially observed. In August 2002, he presented to an outside hospital with a white blood cell (WBC) count of 75 Â 10 9 /l and 80% myeloid blasts in the bone marrow. A diagnosis of AML M2 in the French-American-British (FAB) classification was established. Cytogenetic study showed again a normal diploid male karyotype. He received induction therapy with cytarabine hydrochloride (ara-C) and idarubicin on a 7 þ 3 regimen (ara-C and idarubicin), and achieved a complete remission. Consolidation treatment with one course of high-dose ara-C (HDAC) was given, after which the patient remained pancytopenic and no further therapy was provided. A bone marrow aspirate 2 months later showed tri-lineage dysplasia with 3% blasts, and a normal diploid male karyotype.
The patient presented to the University of Texas M D Anderson Cancer Center (MDACC) in April 2003 seeking treatment options for persistent pancytopenia. Observation was recommended because he was not transfusion dependent and had no signs and symptoms of disease. In August 2004, the patient was seen again at MDACC and was found to have relapsed disease. A bone marrow aspirate demonstrated 28% blasts and a normal diploid male karyotype. Imunophenotypic analysis by flow cytometry showed that the blasts had a myeloid imunophenotype. They were positive for CD13, CD33, CD34, CD117 and myeloperoxidase (partial), with aberrant partial expression of CD7, and negative for CD19. The patient was offered therapy with HDAC chemotherapy regimen, but he returned home and received re-induction therapy with a 7 þ 3 regimen. He again developed pancytopenia and returned to MDACC. A bone marrow examination performed on day 79 of re-induction demonstrated 10% blasts and a normal diploid male karyotype. He then received a therapy with a combination of HDAC and fludarabine twice daily for 5 days, but received only one cycle owing to protracted pancytopenia and multiple infections. A bone marrow examination performed 3 months after the completion of chemotherapy demonstrated persistent disease with 10% blasts and a normal diploid male karyotype; the patient returned home.
In May 2005, the patient presented again to MDACC. A complete blood count demonstrated WBC 1.5 Â 10 9 /l, hemoglobin 10.4 g/dl, platelets 43 Â 10 9 /l and 22% circulating blasts. Bone marrow examination showed 62% blasts with an imunophenotype essentially identical to the analysis performed in August 2004. Conventional cytogenetic studies demonstrated 46,XY,t(3;21)(p21;q22) in eight metaphases, and a normal male diploid karyotype in 12 metaphases ( Figure 1 ). Fluorescence in situ hybridization (FISH) using a Vysis LSI bcr/abl ES probe (Vysis, Downers Grove, IL, USA) on 500 interphases was negative for the presence of a clone with the BCR-ABL1 rearrangement. FISH using a Vysis LSI ETO/AML1 probe performed on metaphases that contained the translocation demonstrated that the breakpoint in 21q22 was telomeric to the AML1 locus. Therapy with pixantrone at a dose of 80 mg/m 2 for 3 days was begun, but discontinued when a bone marrow examination on day 22 showed 74% blasts. He then received two cycles of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) at a dose of 200 mg three times daily for 14 days, which transiently reduced the bone marrow blast count to 56% after the first course, only to return to 73% blasts after a second course. At the patient's request, therapy was stopped for 4 weeks, during which time he received only hydroxyurea orally to control his high WBC. Repeat bone marrow examination performed in August 2005 showed a hypercellular marrow (80%) with 83% myeloperoxidasepositive blasts. Karyotypic analysis showed 46,XY,t(9;22) (q34;q11.2)[17]/46,XY,der(9) t(9;22)(q34;q11.2) inv(9)(p12q32), der(22) t(9;22) [2] /46,XY [1] . FISH studies were performed using a locus-specific BCR/ABL1 extra signal dual-color translocation probe (Vysis). These studies demonstrated double-fusion signals, one major and one minor, in 92.5% of the interphases. This pattern is most often seen in Ph-positive acute lymphoblastic leukemia. The patient began a 28-day course of combined therapy consisting of imatinib mesylate (600 mg daily) and the potent vascular endothelial growth factor receptor inhibitor PTK-787 (250 mg orally three times daily). After 1 week, FISH studies showed BCR/ABL1 rearrangement in 99% of the interphases. Three weeks into therapy, the patient was admitted to the hospital with fever, cough, and left upper and lower lobe pulmonary infiltrates. Repeat bone marrow examination on day 28 of treatment showed 62% blasts, and karyotypic analysis revealed 46,XY,t(9;22)(q34;q11.2)[18]/46,XY,der(9)inv(9)(p12q32)t (9;22)(q34;q11.2),der(22)t(9;22) [1] . FISH studies demonstrated double-fusion signals in 92.5% of the interphases. A fusion transcript encoding the p190 BCR-ABL1 protein was detected by real-time polymerase chain reaction; the ratio of BCR-ABL1 to ABL1 transcripts was greater than 100. DNA sequence analysis of the BCR/ABL1 codons 221-421 failed to detect any mutations. Owing to a lack of response, therapy with imatinib and PTK-787 was stopped, and therapy with AMN107 commenced at a dose of 400 mg twice daily, along with broad-spectrum antibiotics and antifungals. A few days later, interferon-a therapy was added. Fine-needle aspiration of the left upper lobe infiltrate demonstrated mucormycosis. Therapy with high dose liposomal amphotericin, caspofungin and leukocyte transfusions was unsuccessful, and the patient expired shortly thereafter.
A late-appearing Ph chromosome is found in less than 1% of patients with AML. 4 Whether cases of Ph-positive AML represent a distinct clinical entity or rather undiagnosed cases of CML in blast phase has been controversial, although most authors contend that Ph-positive AML is a bona fide entity. 4, 5 Several observations support this notion. First, although most FAB subtypes may present with the Ph chromosome, these cases tend to demonstrate a high degree of immaturity and present as M0, M1 or M2 subtypes. 5 This immaturity is usually reflected immunophenotypically; many cases exhibit markers of poorly differentiated AML (CD11b þ , low expression of CD65 and absence of CD14 and CD15), usually coexpressed with lymphoid-associated markers (CD10, CD19, CD20, Cd7 and terminal deoxynucleotidyl transferase (TdT)), suggesting leukemic transformation of a primitive myeloid/lymphoid stem cell. 4 In this report, the blasts were initially negative for CD19, but subsequently showed partial coexpression of CD19 upon demonstration of the Ph chromosome. Second, Ph-positive AML cases have higher initial WBC counts and poorer responses to conventional induction chemotherapy than Ph-negative AML cases. Also, Ph-positive AML tends to evolve from MDS characterized by severe dysplastic features and pancytopenia. Ph-positive AML and Ph-positive MDS can present with M-bcr, m-bcr, or both breakpoints, 5 in contrast with the M-bcr rearrangement consistently seen in all patients with CML. In fact, m-bcr breakpoints have been more frequently reported than M-bcr in Ph-positive AML, further indicating that this cytogenetic abnormality may contribute to terminal leukemogenesis. Extramedullary involvement is also encountered more frequently in patients with Ph-positive AML. With the exception of extramedullary involvement, the case presented in this report demonstrated all of the features associated with Ph-positive AML. Finally, detection of the Ph chromosome 36 months after the initial diagnosis in two clones suggests that the Ph chromosome was a secondary abnormality, representing either 22 21 der(3) 3 der(21) 21 Figure 1 Partial G-banded karyotype showing the t(3;21) (p21;q22).
Letters to the Editor clonal evolution or reflecting a state of genetic instability in a bone marrow with previous genetic aberrations.
It has been well documented that the risk of development of AML following therapy with alkylating agents and DNA topoisomerase II inhibitors increases 50-to 100-fold, usually involving balanced translocations of chromosomes 11q23 or 21q22. The t(3;21)(q26;q22) has been reported in AML primarily following therapy with topoisomerase II inhibitors. In this translocation, the core-binding factor alpha (CBFa) gene may be fused to either of two different genes on chromosome band 3q26: EBER-associated protein (EAP), which encodes the ribosomal protein L22, and MDS1, which encodes a small polypeptide of unknown function. Both chimeric genes transactivate the macrophage colony-stimulating factor receptor (CSF1R) promoter. Rarely, CBFa has been found fused to EVI1. Our patient presented with a translocation involving band 21q22, which raised the possibility of a rearrangement involving the AML1 locus at 21q22. However, FISH using a locus-specific probe for AML1 performed on metaphases know to contain the translocation demonstrated that the probe remained on the derivative chromosome 21. Thus, the breakpoint was telomeric to this locus. To the best of our knowledge, t(3;21) with breaks at 3p21 and 21q22 has never been reported previously in AML, either alone or associated with other karyotypic abnormalities. Shi et al. 6 reported on 11 patients with AML or MDS and treatment-related breakpoints at 3p21. Among these patients, one with MDS harbored the t(3;21)(p21;q22) abnormality. The same abnormality has been described in one patient with a primitive neuroectodermal tumor of the pleura. However, in both cases, t(3;21)(p21;q22) was found in the context of a complex karyotype. In the present case, cytogenetic studies performed after one cycle of the topoisomerase II inhibitor, pixantrone, and two cycles of the histone deacetylase inhibitor, SAHA, revealed the disappearance of the t(3;21) and the development of a late-appearing Ph chromosome. It has been suggested that the origin of the lateappearing Ph chromosome may be strongly associated with the use of topoisomerase II inhibitors. In a recent review of the literature, 22 of 25 patients with CML, ALL or AML who developed late-appearing Ph chromosome had been exposed previously to topoisomerase II inhibitors. 7 The latency period between chemotherapy and appearance of the Ph chromosome ranged from 4 to 90 months. Although in our case the latency period was only 3 months, the possibility that the Ph chromosome appearance was related to pixantrone therapy cannot be excluded.
Finally, successful therapy with Abl1 tyrosine kinase inhibitors for Ph-positive AML is infrequent. 8 This patient failed therapy with high-dose imatinib and subsequently with AMN107, an Abl1 kinase inhibitor 30-fold more potent than imatinib. Because imatinib is associated with hematologic responses in 52% of patients with CML in myeloid blast phase, and AMN107 is associated with hematologic response in 57% of patients who had previously failed imatinib (Kantarjian et al. Blood 2005;106: 15a, abstract), the lack of response was unexpected. As DNA sequencing demonstrated no mutations in the BCR-ABL1 kinase domain, a possible explanation for this phenomenon may be overexpression of the BCR-ABL1 transcript. Regardless, our observations suggest that a late-appearing Ph chromosome in patients with AML may represent a secondary event that is related to chemotherapy, particularly topoisomerase II inhibitors, and which confers a poor prognosis and lack of response to tyrosine kinase inhibitors.
